Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds

Oslo, 14 November 2024: Reference is made to the stock exchange announcement by Circio Holding ASA (OSE:CRNA) ("CIRCIO" or the "Company") on 12 November 2024, regarding the requested conversion of convertible bonds by Atlas Special Opportunities, LLC.

The share capital increase has now been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The Company's new share capital is NOK 25,184,037.00 divided into 41,973,395 shares, each with a nominal value of NOK 0.60.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: [email protected]

Lubor Gaal, CFO
Phone: +34 683343811
Email: [email protected]

About Circio

Building next generation RNA therapeutics
Circio Holding ASA is a biotechnology company developing novel circular RNA gene therapies and immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) expression platform for genetic medicine. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed in multiple disease settings, including cell and gene -therapy and chronic diseases. The circVec platform has demonstrated enhanced and more durable protein expression vs. classic mRNA vector systems and has the potential to become the new gold-standard for DNA and virus-based therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in two clinical trials: RAS-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway. These studies are being run through academic and industry collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.